P. Dayer

P. Dayer, S. Benhamou, A. Hirvonen, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow

P. Dayer, P. Piletta, H. Porchet, 2004, European Journal of Clinical Pharmacology.

Objective assessment of clonidine analgesia in man and influence of naloxone.

P. Dayer, P. Piletta, H. Porchet, 1990, Life sciences.

Contribution of monoaminergic modulation to the analgesic effect of tramadol.

P. Dayer, J. Desmeules, V. Piguet, 1996, British journal of clinical pharmacology.

[Duality of the analgesic effect of tramadol in humans].

P. Dayer, L. Collart, C. Luthy, 1993, Schweizerische medizinische Wochenschrift.

Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots

Y. Daali, P. Dayer, B. Walder, 2014, Clinical pharmacology and therapeutics.

QT interval prolongation in patients on methadone with concomitant drugs.

P. Dayer, G. Ehret, J. Desmeules, 2004, Journal of clinical psychopharmacology.

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.

T. Kronbach, P. Dayer, M. Eichelbaum, 1984, Biochemical and biophysical research communications.

Polymorphism in drug metabolism.

L. Balant, P. Dayer, J. Fabre, 1978, British medical journal.

Differences in Kinetic Properties of Drugs: Implications as to the Selection of a Particular Drug for Use in Patients with Renal Failure With Special Emphasis on Antibiotics and β-Adrenoceptor Blocking Agents

L. Balant, P. Dayer, J. Fabre, 1980, Clinical pharmacokinetics.

Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes

P. Beaune, T. Leemann, P. Dayer, 1996, European Journal of Clinical Pharmacology.

Uptake/Efflux Transport of Tramadol Enantiomers and O-Desmethyl-Tramadol: Focus on P-Glycoprotein

Y. Daali, P. Dayer, J. Desmeules, 2009, Basic & clinical pharmacology & toxicology.

Simultaneous Enantioselective Determination of Underivatized β-Blocking Agents and their Metabolites in Biological Samples by Chiral Ion-Pairing High-Performance Liquid Chromatography

T. Leemann, P. Dayer, 1988 .

Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity

P. Dayer, P Dayer, T Leemann, 1989, Clinical pharmacology and therapeutics.

Changes in serum albumin and α1‐acid glycoprotein concentrations during pregnancy: an analysis of fetal‐maternal pairs

P. Dayer, B. Krauer, R. Anner, 1984, British journal of obstetrics and gynaecology.

Incorporation of flurbiprofen in a 4-drug cytochrome p450 phenotyping cocktail.

Y. Daali, Mallorie Clément, P. Dayer, 2014, Basic & clinical pharmacology & toxicology.

Role of P‐glycoprotein in the Uptake/Efflux Transport of Oral Vitamin K Antagonists and Rivaroxaban through the Caco‐2 Cell Model

Y. Daali, V. Rollason, P. Bonnabry, 2013, Basic & clinical pharmacology & toxicology.

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

P. Dayer, J. Goldstein, U. Meyer, 1998, The Journal of pharmacology and experimental therapeutics.

Identification of New Human CYP 2 C 19 Alleles ( CYP 2 C 19 * 6 and CYP 2 C 19 * 2 B ) in a Caucasian Poor Metabolizer of Mephenytoin 1

P. Dayer, J. Goldstein, U. Meyer, 1998 .

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

G R Wilkinson, P. Dayer, J. Goldstein, 1998, The Journal of pharmacology and experimental therapeutics.

A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry.

Y. Daali, P. Dayer, F. Gumy-Pause, 2012, Rapid communications in mass spectrometry : RCM.

Drug–drug interactions of new active substances: mibefradil example

P. Dayer, S. Vožeh, S. Vozeh, 1999, European Journal of Clinical Pharmacology.

ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.

P. Dayer, C. Korff, J. Desmeules, 2011, Pharmacogenomics.

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

D. Hochstrasser, Y. Daali, P. Dayer, 2009, The Pharmacogenomics Journal.

Impact of environmental and genetic factors on codeine analgesia

P. Dayer, J. Desmeules, M. Gascon, 2004, European Journal of Clinical Pharmacology.

Central analgesic effect of acetaminophen but not of aspirin

P. Dayer, P. Piletta, H. Porchet, 1991, Clinical pharmacology and therapeutics.

The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro.

T. Leemann, P. Dayer, S. Ferrari, 1991, Life sciences.

Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

L. Balant, P. Dayer, A. Allaz, 1980, Clinical Therapeutics.

Influence of input rates on (±)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers

P. Dayer, H. Porchet, V. Carrara, 2004, European Journal of Clinical Pharmacology.

CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships.

P. Dayer, K. Husgafvel‐Pursiainen, S. Benhamou, 2000, European journal of cancer.

High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers.

P. Dayer, S. Benhamou, A. Hirvonen, 2000, Cancer research.

A randomized, controlled trial validates a peripheral supra-additive antihyperalgesic effect of a paracetamol-ketorolac combination.

D. Salomon, Y. Daali, P. Dayer, 2011, Basic & clinical pharmacology & toxicology.

The Pharmacology of Tramadol

P. Dayer, J. Desmeules, L. Collart, 2012, Drugs.

Simultaneous tubular excretion and reabsorption of pindolol in man

L. Balant, P. Dayer, K. Muir, 2004, European Journal of Clinical Pharmacology.

New approaches to the pharmacotherapy of neuropathic pain

P. Dayer, J. Desmeules, M. Besson, 2008, Expert review of clinical pharmacology.

Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.

P. Bonnabry, T. Leemann, P. Dayer, 1994, Life sciences.

Steric configuration and polymorphic oxidation of lipophilic beta-adrenoceptor blocking agents: in vivo — in vitro correlations

T. Kronbach, T. Leemann, P. Dayer, 1985 .

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).

T. Leemann, P. Dayer, J. Desmeules, 1988, Biochemical and biophysical research communications.

[Recurrent pericarditis induced by mesalazine (5-ASA)].

P. Dayer, J. Desmeules, N. Vogt, 1994, Therapie.

Evidence of Drug-Drug Interactions through Uptake and Efflux Transport Systems in Rat Hepatocytes: Implications for Cellular Concentrations of Competing Drugs

Y. Daali, P. Dayer, P. Millet, 2013, Drug Metabolism and Disposition.

Microsoft Word-7168058-file00

Y. Daali, P. Dayer, P. Millet, 2013 .

Association between lung cancer and microsomal epoxide hydrolase genotypes.

P. Dayer, S. Benhamou, A. Hirvonen, 1998, Cancer research.

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

D. Hochstrasser, P. Dayer, J. Desmeules, 2006, European Journal of Clinical Pharmacology.

Propranolol treatment in children with tetralogy of Fallot alters the response to isoprenaline after surgical repair.

P. Dayer, C. Jaccard, M. Berner, 1988, British heart journal.

P. Bonnabry, P. Dayer, J. Desmeules, 2015, European journal of internal medicine.

Role of alcohol dehydrogenase 3 and cytochrome P‐4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract

P. Dayer, P. Ward, S. Benhamou, 2000, International journal of cancer.

Simultaneous stereoselective analysis of tramadol and its main phase I metabolites by on-line capillary zone electrophoresis-electrospray ionization mass spectrometry.

S. Fanali, S. Cherkaoui, J. Veuthey, 2000, Journal of chromatography. A.

Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo

T. Kronbach, P. Dayer, U. Meyer, 1985, Clinical pharmacology and therapeutics.

The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

C Skoda, T. Kronbach, P. Dayer, 1986, Xenobiotica; the fate of foreign compounds in biological systems.

Debrisoquine‐type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation

T. Kronbach, P. Dayer, R. Gasser, 1984, FEBS letters.

Evidence for altered catalytic properties of the cytochrome P‐450 involved in sparteine oxidation in poor metabolizers

P. Dayer, M. Eichelbaum, U. Meyer, 1987, Clinical pharmacology and therapeutics.

Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents

L. Balant, P. Dayer, J. Fabre, 2004, European Journal of Clinical Pharmacology.

Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers.

T. Leemann, P. Dayer, G. Merier, 1986, Journal of Cardiovascular Pharmacology.

Studies on the molecular basis of polymorphic drug oxidation (debrisoquine/sparteine-type) in man

T. Kronbach, P. Dayer, U. Meyer, 1985 .

Re: Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers.

P. Dayer, P. Ward, S. Benhamou, 1998, Journal of the National Cancer Institute.

Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite.

Patrice Mangin, Christian Staub, Caroline Samer, 2011, Journal of pharmaceutical and biomedical analysis.

[Genetic polymorphism and drug interactions: their importance in the treatment of pain].

P. Dayer, J. Desmeules, C. Samer, 2005, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.

Y. Daali, P. Dayer, M. Krajinovic, 2012, Current drug metabolism.

Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

Y. Daali, P. Dayer, P. Fontana, 2010, Current drug metabolism.

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

T. Leemann, P. Dayer, C. Transon, 1996, European Journal of Clinical Pharmacology.

Role of NAD(P)H:quinone oxidoreductase polymorphism at codon 187 in susceptibility to lung, laryngeal and oral/pharyngeal cancers

P. Dayer, S. Benhamou, A. Hirvonen, 2001 .

Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking.

P. Dayer, S. Benhamou, A. Hirvonen, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.

Y. Daali, P. Dayer, J. Desmeules, 2007, Clinical therapeutics.

The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients.

L. Balant, P. Dayer, J. Fabre, 1982, Kidney international.

Point/Counterpoint Point: Myeloperoxidase 463 G3 A Polymorphism and Lung Cancer Risk 1

P. Dayer, S. Benhamou, A. Hirvonen, 2002 .

Effects of CYP2D6 activity and tobacco on larynx cancer risk.

P. Dayer, S. Benhamou, C. Bouchardy, 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population.

P. Dayer, K. Husgafvel‐Pursiainen, S. Benhamou, 1997, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk.

P. Dayer, S. Benhamou, H. Wikman, 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates

P. Dayer, D. Suvà, J. Desmeules, 2009, Drug safety.

Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition

A. Munafo, J. Biollaz, P. Dayer, 1992, Antimicrobial Agents and Chemotherapy.

Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients.

P. Dayer, J. Cherpillod, B. Vaudaux, 1996, The Journal of antimicrobial chemotherapy.

Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver.

T. Leemann, P. Dayer, C. Transon, 1993, Life sciences.

Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam

P. Bonnabry, T. Leemann, P. Dayer, 2004, European Journal of Clinical Pharmacology.

Serum protein binding of diazepam and propranolol in the feto-maternal unit from early to late pregnancy.

P. Dayer, H. Nau, P. Bischof, 1986, British journal of obstetrics and gynaecology.

Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis

P. Bonnabry, P. Dayer, C. Combescure, 2012, PLoS medicine.

The genetic controlof bufuralol metabolisminman

L. Balant, P. Dayer, J. Fabre, 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].

L. Balant, P. Dayer, J. Fabre, 1983, Schweizerische medizinische Wochenschrift.

Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein.

Y. Daali, P. Dayer, J. Desmeules, 2008, Current drug metabolism.

THE DURATION OF ACTION OF PINDOLOL and ITS RELATION TO PLASMA LEVELS

L. Balant, P. Dayer, J. Fabre, 1979 .

Patients' Representations of Antidepressants: A Clue to Nonadherence?

P. Dayer, C. Cedraschi, J. Desmeules, 2007, The Clinical journal of pain.

A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes.

Y. Daali, S. Cherkaoui, P. Dayer, 2004, Journal of pharmaceutical and biomedical analysis.

Psychological distress in fibromyalgia patients: a role for catechol-O-methyl-transferase Val158met polymorphism.

P. Dayer, C. Cedraschi, F. Curtin, 2012, Health Psychology.

[Clinical pharmacology in practice].

P. Dayer, N. Vogt, 1994, Schweizerische medizinische Wochenschrift.

Identification and weighting of the most critical “real-life” drug–drug interactions with acenocoumarol in a tertiary care hospital

V. Rollason, P. Bonnabry, P. Dayer, 2013, European Journal of Clinical Pharmacology.

Prioritization methodology for the monitoring of active pharmaceutical ingredients in hospital effluents.

Y. Daali, P. Bonnabry, P. Dayer, 2015, Journal of environmental management.

Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers.

P. Dayer, L. Juillerat-Jeanneret, P. Leuenberger, 1998, Pulmonary Pharmacology & Therapeutics.

Contribution of cytochrome P-4502 D 6 phenotype to the neuromodulatory effects of dextromethorphan DESMEULES ,

P. Dayer, J. Desmeules, A. Allaz, 2017 .

Randomized Trial Dual Reuptake Inhibitor Milnacipran and Spinal Pain Pathways in Fibromyalgia Patients : A Randomized , Double-Blind , Placebo-Controlled Trial

Y. Daali, P. Dayer, C. Cedraschi, 2013 .

In vitro forecasting of drugs that may interfere with codeine bioactivation

P. Dayer, J. Desmeules, R. Strffierni, 1992, European Journal of Drug Metabolism and Pharmacokinetics.

Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

L. Balant, P. Dayer, J. Aeschlimann, 2004, European Journal of Clinical Pharmacology.

Differential consequences of renal failure on the pharmacokinetics of Oxprenolol and its main metabolite

L. Balant, P. Dayer, J. Fabre, 1983, European Journal of Drug Metabolism and Pharmacokinetics.

T. Leemann, P. Dayer, K. Devi, 2004, European Journal of Clinical Pharmacology.

[Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency].

L. Balant, P. Dayer, J. Fabre, 1981, Schweizerische medizinische Wochenschrift.

Why is codeine unreliable for cancer pain control

P. Dayer, J. Desmeules, 1988 .

Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot

Y. Daali, P. Dayer, J. Déglon, 2012, Clinical pharmacology and therapeutics.

The mixed analgesic effects of tramadol enantiomers

P. Dayer, J. Desmeules, V. Piguet, 1999 .

Neurophysiologic evidence for a central sensitization in patients with fibromyalgia.

P. Dayer, T. Vischer, C. Cedraschi, 2003, Arthritis and rheumatism.

Preliminary CommuniCation

P. Dayer, J. Desmeules, A. L'Huillier, 2009 .

Advances with analgesics and NSAIDs for the treatment of spinal disorders.

P. Dayer, C. Cedraschi, J. Desmeules, 2002, Baillière's Best Practice & Research : Clinical Rheumatology.

Medical-ethical guidelines for genetic investigations in humans.

F. Gutzwiller, P. Dayer, G. Pescia, 1994, Schweizerische medizinische Wochenschrift.

Lung cancer risk in relation to mephenytoin hydroxylation activity.

P. Dayer, S. Benhamou, C. Bouchardy, 1997, Pharmacogenetics.

Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite.

Y. Daali, P. Dayer, J. Desmeules, 2011, Journal of pharmaceutical and biomedical analysis.

Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model.

Y. Daali, P. Dayer, C. Csajka, 2013, The Journal of antimicrobial chemotherapy.

Propranolol treatment in children with tetralogy of Fallot alters the response to isoprenaline after surgical repair.

P. Dayer, C. Jaccard, M. Berner, 1988, British heart journal.

[Drug interactions of midazolam].

P. Dayer, F. Waldvogel, M. Gascón, 1989, Schweizerische medizinische Wochenschrift.

Use of the label "litigation neurosis" in patients with somatoform pain disorder.

P. Dayer, P. Guex, J. Desmeules, 1998, General hospital psychiatry.

P‐glycoprotein is not involved in the differential oral potency of naloxone and naltrexone

Y. Daali, P. Dayer, J. Desmeules, 2009, Fundamental & clinical pharmacology.